sur ABIVAX (EPA:ABVX)
Abivax Reports Full Year 2025 Financial Results and Business Updates
Abivax, a biotechnology company, has released its financial results for 2025. Despite an increase in research and development expenses, mainly due to clinical trials for obefazimod in ulcerative colitis and Crohn’s disease, the company finished 2025 with €530.4 million in cash and a projected runway into Q4 2027.
In 2025, Abivax raised approximately €597.2 million through a public offering. The company's operating loss increased to €246.1 million, driven by higher general and administrative costs. This cost surge was primarily linked to rising personnel expenses.
The year marked a pivotal point for Abivax with strategic leadership appointments to prepare for potential commercialization of obefazimod. Notably, Michael Nesrallah was appointed Chief Commercial Officer to strengthen commercial capabilities ahead of obefazimod's anticipated market launch.
Looking forward, the company plans to announce Q1 2026 financial results in May and expects key clinical trial results for its ulcerative colitis treatment in late Q2 2026.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX